Over 5,000 Physicians Gather at Korean Laser Dermatology Conference—Medytox Showcases ‘Botulinum Toxin for Energy Device Combination’

Over 5,000 Physicians Gather at Korean Laser Dermatology Conference—Medytox Showcases ‘Botulinum Toxin for Energy Device Combination’

📌 Key Takeaways

  • On May 6, 2026, the 52nd Korean Society for Laser Medicine and Surgery (KSLS) Spring International Conference was held at COEX Seoul, attracting over 5,000 physicians from Korea and abroad
  • Korean botulinum toxin manufacturer Medytox set up the largest exhibition booth, showcasing two products: Coretox and Innotox
  • The spotlight was on the concept of “botulinum toxin that can be combined with energy devices like HIFU and RF”—signaling that combination treatments delivering multiple effects in a single visit are becoming mainstream in Korean aesthetic medicine in 2026

“Can you do botulinum toxin and HIFU on the same day?” Until just a few years ago, this was a combination that made many physicians cautious.

But in Korea in 2026, a new generation of botulinum toxin products designed specifically for same-day combination with energy devices is drawing major attention at academic conferences.

What Is the Korean Society for Laser Medicine and Surgery?

💡 About KSLS
The Korean Society for Laser Medicine and Surgery (KSLS) is an academic organization focused on laser and energy-based devices in dermatology and aesthetic medicine. It holds international conferences twice a year.Korean aesthetic medicine often leads global trends, and techniques or protocols presented at KSLS conferences typically spread to Japan and other countries within 1-2 years.

Two Products Showcased by Medytox—What’s New?

📊 Medytox’s Key Products at KSLS 2026

Coretox: A botulinum toxin formulation composed solely of 150kDa (kilodalton) pure neurotoxin. With fewer “complex proteins” than conventional products, it is designed to reduce the risk of immune response that can cause diminished efficacy with repeated use
Innotox: A liquid-form botulinum toxin with no animal-derived ingredients. Requires no reconstitution (mixing powder with saline), and was exhibited as “a formulation optimized for combination with energy devices”

What Is “Botulinum Toxin × Device Combination Therapy”?

The most notable message at this exhibition was that “Innotox is suitable for combination with energy devices.”

HIFU (High-Intensity Focused Ultrasound) delivers focused ultrasound energy to deep skin layers, causing thermal coagulation to achieve lifting effects. Well-known devices include Ultherapy and Shrink. RF (Radio Frequency) uses electromagnetic waves to heat skin from within, stimulating collagen production.

💡 Why Is “Botulinum Toxin × HIFU” Gaining Attention?
HIFU and RF are heat-based treatments that temporarily sensitize the skin post-procedure. Traditionally, physicians were cautious about performing botulinum toxin and HIFU on the same day.However, with new liquid-form and pure-component botulinum toxin formulations, research suggests this combination may be safer, enabling “completion of lifting + wrinkle reduction in a single visit”—a key goal of combination therapy protocols.

What 5,000+ Attendees Reveal About Korea’s “Learning Culture”

Over 5,000 physicians attended this conference—far exceeding Korea’s total number of board-certified dermatologists (approximately 2,950). This means many non-dermatologist physicians also participated.

Korea has a deeply rooted culture of physicians actively seeking the latest techniques in aesthetic medicine, with academic conferences functioning as practical technology update venues. This is one reason Korean aesthetic medicine leads globally.

NERO Editorial Perspective
The trend from this exhibition is clear: the keyword for Korean aesthetic medicine in 2026 is “optimization of combination therapy”—pursuing protocols that combine botulinum toxin, fillers, HIFU, and RF to deliver maximum results in a single visit.In Japan and other markets, patient inquiries about “receiving botulinum toxin and HIFU on the same day” are increasing, but feasibility depends on which formulation is used.

Asking your physician “Can you propose a botulinum toxin-device combination treatment?” may be the gateway to more efficient aesthetic medicine. However, always defer to your physician’s judgment on which combination suits your individual case.

Summary

  • The KSLS Spring Conference (May 6, 2026) attracted over 5,000 physicians
  • Medytox showcased Coretox (pure-component) and Innotox (liquid-form, device-compatible) in its largest booth
  • “Botulinum toxin × HIFU/RF combination therapy” is emerging as a major trend in Korean aesthetic medicine in 2026
  • Impact on Japan and other markets expected within 1-2 years—“availability of combination therapy proposals” may become a new criterion for clinic selection

Frequently Asked Questions

What is Medytox? Is it used in Japan?
Medytox is a major South Korean biopharmaceutical company specializing in botulinum toxin formulations. Innotox is used in some Japanese clinics, but regulatory approval status varies by product. Before treatment, ask your physician: “Is this product approved in Japan?”
What’s the difference between HIFU and RF?
HIFU (High-Intensity Focused Ultrasound) focuses ultrasound energy on deep layers (SMAS fascia) to cause thermal coagulation, producing tightening and lifting effects. RF (Radio Frequency) uses electromagnetic waves to heat skin from within, stimulating collagen production. HIFU targets “deep and focused,” while RF works “broad and uniform.” Choice depends on treatment goals and areas.
Is it safe to receive botulinum toxin and HIFU on the same day?
It depends on the botulinum toxin formulation used, HIFU power settings, and treatment areas. Generally, “same-day combination requires careful attention to sequence and location,” and physicians make individual assessments. If you wish to receive combination therapy in one visit, discuss this during your initial consultation and follow your physician’s guidance.
K

Kenichi Adachi Editor-in-Chief, NERO DOCTOR/BEAUTY

This article is reviewed and curated by Kenichi Adachi, Editor-in-Chief of NERO, a U.S. Registered Nurse (BSN) and MBA holder, based on primary medical data from leading global sources. NERO maintains an independent editorial policy free from advertiser influence, dedicated to delivering aesthetic medicine information you can choose with understanding, not emotion.

Sources
Seoul Economic Daily, “Medytox Showcases Aesthetic Medical Portfolio at Korean Dermatology Conference,” May 6, 2026

NERO Kenichi Adachi